Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) in Patients With Coronavirus Disease 2019 (COVID-19)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Giessen
- Enrollment
- 900
- Locations
- 1
- Primary Endpoint
- Incidence of AKI
Study Overview
Brief Summary
Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.
Detailed Description
Beginning in December 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (SARS-CoV-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria
Exclusion Criteria
- •Patients aged less than 18 years
- •Patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate <30 ml/min/1.73 m2)
- •Patients receiving maintenance dialysis
- •Recipients of solid-organ transplantation
Outcomes
Primary Outcomes
Incidence of AKI
Time Frame: 30 days post-hospital admission
Serial assessment of serum creatinine and urine output
Cystatin C as indicator of mortality
Time Frame: 30 days post-hospital admission
All-cause mortality
Cystatin C as indicator of renal disease
Time Frame: 30 days post-hospital admission
AKI and acute kidney disease (AKD)
Cystatin C as indicator of disease severity
Time Frame: 30 days post-hospital admission
Rate of intensive care unit admission
Cystatin C as indicator of respiratory illness
Time Frame: 30 days post-hospital admission
Ventilator-free days
Secondary Outcomes
No secondary outcomes reported